BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares
Science Advances · 02.01.2026 · 12 (1)
DOI: 10.1126/sciadv.aeb6424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 02.01.2026. Verfasst von Xiaoyu Huang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: B-Cell Maturation Antigen, Antigens, CD19, Myasthenia Gravis, Proteomics. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Jiangsu Commission of Health, National Natural Science Foundation of China, Basic Research Program of Jiangsu.
Abstract (Originalsprache)
Myasthenia gravis (MG) is an autoimmune disorder characterized by B cell dysfunction. Here, we designed B cell maturation antigen (BCMA)/CD19 chimeric antigen receptor T cell (CAR T cell) therapy for six refractory MGs, demonstrating favorable safety with grade 1 cytokine release syndrome observed. CAR T cell expansion induced profound B cell depletion, a sustained reduction in acetylcholine receptor (AChR) antibody titers, and symptom improvement. Five patients achieved drug-free remission with minimal manifestations by month 6, persisting through the 12-month follow-up despite B cell reconstitution. Reconstituted B cells showed naïve predominance with diminished AChR specificity and functional capacities. Olink proteomics revealed up-regulation of anti-inflammatory factors, along with down-regulation of proinflammatory molecules. Single-cell sequencing revealed that age-associated B cells (ABCs) were up-regulated in a relapsed patient, and differential gene analysis indicated that Fc receptor-like 5 (FCRL5) expression was elevated in ABCs, whereas CAR T cell responders exhibited a down-regulated trend. Notably, similar ABC expansion and FCRL5 up-regulation occurred in rituximab-relapsed patients. Our findings support BCMA/CD19 CAR T cell therapy as feasible, tolerable, and effective in MG, identifying FCRL5 as a previously unidentified target in relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Neurology and Institute of Neuroimmunology, Tianjin Medical University General Hospital, Tianjin, China.
- Clinical Research Institute, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
ORCID-Profile: Xiaoyu Huang, Zhouao Zhang, Dan Liu, Tiancheng Luo, Xueting An, Mingjin Yang, Gang Wang, Huizhong Li, Jiang Cao, Zengtian Sun, Xue Du, Zhouyi Wang, Xinyan Guo, Tianyu Ma, Deyou Peng, Guoyan Qi, Shenghua Zong, Yanting Ding, Guiyun Cui, Ming Shi, Junnian Zheng, Yong Zhang
Förderung
- Jiangsu Commission of Health
- National Natural Science Foundation of China
- Basic Research Program of Jiangsu
- Construction Project of High Level Hospital of Jiangsu Province
- Young academic leaders of Jiangsu Qinglan Project
- Open Project of Key Laboratory of Colleges and Universities in Jiangsu Province
Zitieren
APA
Huang, X., Zhang, Z., Liu, D., Luo, T., An, X., Yang, M., Li, S., Wang, G., Li, H., Cao, J., Sun, Z., Du, X., Wang, Z., Guo, X., Ma, T., Peng, D., Qi, G., Zong, S., Ding, Y., …, & Zhang, Y. (2026). BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares. Science Advances, 12(1). https://doi.org/10.1126/sciadv.aeb6424
Vancouver
Huang X, Zhang Z, Liu D, Luo T, An X, Yang M, et al. BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares. Science Advances. 2026;12(1). doi:10.1126/sciadv.aeb6424
BibTeX
@article{Huang2026,
author = {Huang, Xiaoyu and Zhang, Zhouao and Liu, Dan and Luo, Tiancheng and An, Xueting and Yang, Mingjin and Li, Shengli and Wang, Gang and Li, Huizhong and Cao, Jiang and Sun, Zengtian and Du, Xue and Wang, Zhouyi and Guo, Xinyan and Ma, Tianyu and Peng, Deyou and Qi, Guoyan and Zong, Shenghua and Ding, Yanting and Cui, Guiyun and Shi, Ming and Zheng, Junnian and Zhang, Yong},
title = {BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {1},
doi = {10.1126/sciadv.aeb6424}
}
EUVIMED